COMy 2022 | The importance of del(17p) as a prognostic factor in myeloma
Jill Corre
• 13 May 2022
In this video, Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, discusses the importance of del(17p) as a poor prognostic factor in multiple myeloma, and compares this to the prognostic value of patients with t(4;14). Dr Corre also discusses two important details to consider with these genomic aberrations: the clonal size of del(17p) and the possibility of TP53 mutation resulting in double-hit myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
